Pasithea Therapeutics Corp. (KTTA) - מכפיל P/E

Pasithea Therapeutics (KTTA) bases its business on managing a network of centers that utilize ketamine infusion to treat depression and chronic pain. The company's operations are exposed to risks of supply chain disruptions for rare reagents and delays in global software testing. Historical price action on GURU.Markets shows a value of -0.80, while the staff of leading neurobiologists remains stable and committed to scientific goals.

Pasithea Therapeutics (KTTA) is optimizing biocomponent supply chains for the development of psychiatric disorder treatments. The ratio of market capitalization to net income, reflected in the company's P/E ratio dynamics, measures the premium for the future success of clinical trials. This coefficient demonstrates investors' willingness to pay a premium per unit of current earnings. This chart allows for the differentiation of accounting metrics from the asset's real value, which determines the fair cost of capital under high-risk conditions.